ECSP993219A - HUMANIZED ANTIBODY SPECIFIC FOR THE HUMAN 4- IBB AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAME - Google Patents
HUMANIZED ANTIBODY SPECIFIC FOR THE HUMAN 4- IBB AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAMEInfo
- Publication number
- ECSP993219A ECSP993219A ECSP993219A ECSP993219A EC SP993219 A ECSP993219 A EC SP993219A EC SP993219 A ECSP993219 A EC SP993219A EC SP993219 A ECSP993219 A EC SP993219A
- Authority
- EC
- Ecuador
- Prior art keywords
- human
- humanized antibody
- antibody
- pharmaceutical composition
- ibb
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229960003444 immunosuppressant agent Drugs 0.000 abstract 1
- 230000001861 immunosuppressant effect Effects 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La invención esta dirigida a los anticuerpos humanizados que especificamente se vinculan con la proteína 4-1BB. Los anticuerpos pueden ser compuestos mediante el implante de las regiones determinantes complementarias (RDC) del anticuerpo monocional del ratón para el 4-1BB humano hacia las porciones restantes del anticuerpo humano y para producir una mayor substitución de los aminoácidos. Además, es una composición farmacéutica que incluye el anticuerpo humanizado que puede ser compuesto y utilizado para tratar enfermedades auto inmunes y suprimir una respuesta inmune. El anticuerpo humanizado de está invención tiene una gran afinidad con el 4-1BB humano y demuestra secuencias similares al anticuerpo humano. Como resultado de esto, el compuesto farmacéutico de la invención puede ser utilizado para tratar enfermedades autoinmunes y actuar como inmunosupresor para los seres humanos, sin muchos efectos secundarios.The invention is directed to humanized antibodies that specifically bind to the 4-1BB protein. Antibodies can be compounded by implanting the complementary determining regions (RDCs) of the mouse monoclonal antibody for human 4-1BB into the remaining portions of the human antibody and to produce increased amino acid substitution. Furthermore, it is a pharmaceutical composition that includes the humanized antibody that can be compounded and used to treat autoimmune diseases and suppress an immune response. The humanized antibody of this invention has a high affinity for human 4-1BB and demonstrates sequences similar to human antibody. As a result of this, the pharmaceutical compound of the invention can be used to treat autoimmune diseases and act as an immunosuppressant for humans, without many side effects.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993219 ECSP993219A (en) | 1999-12-07 | 1999-12-07 | HUMANIZED ANTIBODY SPECIFIC FOR THE HUMAN 4- IBB AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAME |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP993219 ECSP993219A (en) | 1999-12-07 | 1999-12-07 | HUMANIZED ANTIBODY SPECIFIC FOR THE HUMAN 4- IBB AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP993219A true ECSP993219A (en) | 2000-02-24 |
Family
ID=42044207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP993219 ECSP993219A (en) | 1999-12-07 | 1999-12-07 | HUMANIZED ANTIBODY SPECIFIC FOR THE HUMAN 4- IBB AND PHARMACEUTICAL COMPOSITION THAT INCLUDES THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP993219A (en) |
-
1999
- 1999-12-07 EC ECSP993219 patent/ECSP993219A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021296A1 (en) | A SPECIFIC HUMANIZED ANTIBODY FOR 4-1BB HUMAN AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT | |
| AR041173A1 (en) | ANTI-IL- 1R1 MONOCLONAL ANTI-BODY THERAPEUTIC HUMAN | |
| ES2572177T3 (en) | Human anti-B7RP1 neutralizing antibodies | |
| GT200600182A (en) | DIRECTED ANTIBODIES AGAINST THE BETA AMYLOID PEPTIDE AND METHOD THAT THEY USE THE SAME | |
| BR0315157A (en) | Methods of treating alzheimer's disease by employing antibodies directed against amyloid beta peptide and compositions thereof | |
| EA200001041A1 (en) | ANTIBODIES TO CD23, THEIR DERIVATIVES AND THEIR THERAPEUTIC APPLICATION | |
| BR9911389A (en) | Peptide composition as an immunogen for the treatment of allergy | |
| MY154009A (en) | Anti-alpha v beta 6 antibodies | |
| CY1107628T1 (en) | HUMAN CTLA-4 ANTIBODIES AND USES | |
| PE20050925A1 (en) | RECOMBINANT ANTI-INTERLEUQUIN HUMANIZED ANTIBODY 10 | |
| CO6231009A2 (en) | ANTIBODIES OX40 ANTAGONISTS AND ITS USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | |
| NO982062D0 (en) | Humanized antibodies to human gp39, compositions containing them, and therapeutic use thereof | |
| CO4850562A1 (en) | PROCESS TO PRODUCE A CONCENTRATED PREPARATION OF ANTIBODIES | |
| AR075790A2 (en) | ANTI-NGF ANTIBODIES NEUTRALIZING HUMANS AS SELECTIVE INHIBITORS OF THE NGF VIA (NEURAL GROWTH FACTOR) | |
| EA200100780A1 (en) | TWEAK ANTAGONISTS AND TWEAK RECEPTORS AND THEIR USE FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES | |
| PE20091449A1 (en) | ANTIGEN BINDING PROTEINS | |
| CO2020012621A2 (en) | Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods for their use | |
| ES2102347T3 (en) | METHODS AND COMPOSITIONS FOR THE USE OF ENV POLYPEPTIDES AND ANTI-ENV ANTIBODIES OF HIV. | |
| AR126001A1 (en) | ANTI-NKG2A ANTIBODIES AND COMPOSITIONS | |
| PE20050962A1 (en) | FULLY HUMAN ANTIBODIES VS HUMAN 4-1BB | |
| CO2025004790A2 (en) | Humanized anti-IL-1r3 antibody and methods of use | |
| BR0210648A (en) | Variant of an immunointeractive molecule, monoclonal antibody, de-immunized form of monoclonal antibody 3b6, method for generating a de-immunized monoclonal antibody, de-immunized antibody molecule, de-immunized antibody, murine monoclonal antibody variant 3b6 de-immunized, variant of a murine monoclonal antibody 3b6 de-immunized for use in humans, method for detecting a blood clot in a human patient, method for detecting a blood clot or an antigen-binding fragment, method for facilitating the dissolution or removal of a blood clot in a human, use of a murine variant-derived monoclonal antibody, and, conjugated | |
| EA200200974A1 (en) | MONOCLONAL ANTIBODIES TO THE HUMAN LDL RECEPTOR, THEIR RECEIVING AND APPLICATION | |
| PE20010046A1 (en) | RECOMBINANT ANTI-IDIOTYPIC ANTIBODIES | |
| Kaur et al. | Evolution bites—Timeworn inefficacious snakebite therapy in the era of recombinant vaccines |